Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Similar documents
HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Heart Failure CTSHP Fall Seminar

Heart Failure Teri Diederich, APRN April 7, Objectives. Heart Failure Statistics 3/29/2016

State-of-the-Art Management of Chronic Systolic Heart Failure

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

Heart Failure (HF) Treatment

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Definition of Congestive Heart Failure

Heart Failure Clinician Guide JANUARY 2018

Heart Failure. Dr. William Vosik. January, 2012

Antialdosterone treatment in heart failure

Summary/Key Points Introduction

Heart Failure Clinician Guide JANUARY 2016

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

HEART FAILURE KEEPING YOUR PATIENT AT HOME

Contemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium

A Guide to the Etiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure. Part I: Etiology and Pathophysiology of Heart Failure

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

Congestive Heart Failure 2015

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Heart Failure Pharmacotherapy An Update

Heart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none

Improving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

LITERATURE REVIEW: HEART FAILURE. Chief Residents

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

HEART FAILURE: PHARMACOTHERAPY UPDATE

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

Long-Term Care Updates

2016 Update to Heart Failure Clinical Practice Guidelines

Pathophysiology: Heart Failure

Heart Failure: Combination Treatment Strategies

Heart Failure Background, recognition, diagnosis and management

Heart Failure A Team Approach Background, recognition, diagnosis and management

Chronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH

Objectives. Outline 4/3/2014

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy

I have no disclosures. Disclosures

Akash Ghai MD, FACC February 27, No Disclosures

Guideline-Directed Medical Therapy

Heart Failure Management Policy and Procedure Phase 1

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018

The Failing Heart in Primary Care

Pre-discussion questions

Congestive Heart Failure: Outpatient Management

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation

Heart Failure Update John Coyle, M.D.

Module 1: Evidence-based Education for Health Care Professionals

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

CLINICAL PRACTICE GUIDELINE

Heart Failure, Anticoagulants, and Medication Reconciliation

Difficult to Treat Hypertension

Balanced information for better care. Heart failure: Managing risk and improving patient outcomes

HEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

M2 TEACHING UNDERSTANDING PHARMACOLOGY

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL

Heart Failure: Current Management Strategies

Heart Failure 101 The Basic Principles of Diagnosis & Management

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

Drugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia

Cardiovascular Pharmacotherapy

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Heart Failure: Guideline-Directed Management and Therapy

Module 1: Evidence-based Education for Health Care Professionals

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Heart Failure. Dr. Alia Shatanawi

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Hypertension (JNC-8)

Advanced Care for Decompensated Heart Failure

Gina G. Mentzer, MD Cardiologist, Heart Failure & Transplant Advanced Integrated Medicine & Surgery (AIMS) Program for Heart Failure April 18 th,

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

Treating HF Patients with ARNI s Why, When and How?

Translating Evidence Based Recommendations Into Practice

Innovation therapy in Heart Failure

Cardiorenal and Renocardiac Syndrome

Congestive Heart Failure Patient Profile. Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption

Heart Failure. GP Update Refresher 18 th January 2018

Updates in Congestive Heart Failure

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

Initiating New Medications in the Management of Heart Failure

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Heart Failure treatment during pregnancy

CONGESTIVE CARDIAC FAILURE. Dr.T.Rajathilagam, M.D., S.R.M. Medical College

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Diastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012

Transcription:

Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. American College of Cardiology Foundation 2013 Objectives: Upon completing the session, the participant will have improved standardization and knowledge of: Systolic and Diastolic Heart Failure (HFrEF and HFpEF) Etiology of HF Common HF medications Common HF therapies Current HF outpatient monitoring tools Heart Failure Incidence and Prevalence Only form of heart disease increasing in prevalence Estimated 5.7 million Americans with HF Projections show that the prevalence of HF will increase 46% from 2012 to 2030, resulting in >8 million people 18 years of age with HF 915, 000 new HF cases annually, HF incidence approaches 10 per 1000 after age 65 At age 40, 1 in 5 lifetime risk of developing HF for both men and women One in 9 deaths has HF mentioned on the death certificate, more costly than all forms of cancer combined Heart Disease and Stroke Statistics 2016 Update A Report From the AHA

HFrEF EF <40% The loss of a critical quantity of functioning myocardial cells after injury to the heart due to: Ischemic Heart Disease Hypertension Idiopathic Cardiomyopathy Infections (e.g., viral or bacterial myocarditis, pericarditis, sepsis) Toxins (e.g., alcohol, illicit drugs or cytotoxic drugs) Valvular Disease Prolonged Arrhythmias Pregnancy Heart Failure Physical Signs Peripheral Edema Jugular Venous Distention Hepatojugular Reflux Hepatomegaly Ascites Basilar Rales/Crackles S3 Gallop Cheyne-Stokes Respiration RAAS Angiotensin II Sympathetic Nervous System Norepinephrine ACE-I ARB Aldosterone Antagonists Beta-block ers Hypertrophy, apoptosis, ischemia, arrhythmias, remodeling, fibrosis Morbidity and Mortality Optimal medical management of HFrEF EF <40% Beta Blockers: block sympathetic nervous system Reduce myocardial oxygen demand Side effects: bradycardia, hypotension, heart block, fatigue Only 3 approved medications/ Referred to as Evidence Based Beta-Blockers: Carvedilol, Bisoprolol, and Metoprolol succinate ACE-I/ARB: Block renin-angiotensin-aldosterone system Reduces afterload by preventing vasoconstriction Relieves symptoms and improves exercise tolerance Side effects: hyperkalemia, elevated creatinine, hypotension Examples: lisinopril, enalapril, losartan, valsartan

Optimal medical management of HFrEF EF < 40% Aldosterone Antagonists: Block aldosterone reduces sodium retention Side effects: hyperkalemia, worsening renal failure Examples: spironolactone (also has anti-androgen effects, so may cause gynecomastia), eplerenone Hydralazine and nitrates Used in combination to replace ACE/ARB in patients with severe renal disease Afterload reduction by vasodilation Added to usual medications for African-American patients Optimal Medical Management of HFpEF NO GUIDELINE-DIRECTED TREATMENT Focus on treating underlying mechanisms Hypertension Atrial fibrillation control heart rates anticoagulation Exercise program Research demonstrates aldosterone antagonists reduce HF hospitalizations TOPCAT study Diuretics for symptom management Optimal medical management of HFrEF Entresto (sacubitril/valsartan) Replaces ACE/ARB in patients with NYHA class II-IV Blocks angiotensin Promotes natriuetic peptides Diuretics Used to relieve fluid retention Improve exercise tolerance Electrolyte depletion a frequent complication Higher doses of diuretics are associated with increased mortality Thiazides Cortex Medulla Inhibit active exchange of Cl-Na in the cortical diluting segment of the K-sparing ascending loop of Henle (Metolazone) Inhibit reabsorption of Na in the distal convoluted and collecting tubule Loop of Henle Collecting tubule (spironolactone, amiliride, trimateren) Loop diuretics Inhibit exchange of Cl-Na-K in the thick segment of the ascending loop of Henle (Lasix, Bumex, Demadex)

Disease Course Symptom Management Daily Weights Consistent, accurate weights is key! Same scale, same time of day, similar clothing Dietary restrictions Sodium intake less than 2000 mg daily Fluid intake goal of 64 ounces Medication adherence Symptom management Symptom Management Recognize decompensation early Daily Weights Weight gain of 2 lbs overnight or 5 lbs in a week is concerning Daily assessment of symptoms Dyspnea Orthopnea Dry cough Abdominal bloating or nausea Edema Take action Notify provider of weight gain or symptoms Medication changes to treat underlying cause of decompensation Increase in diuretics Assure adherence to dietary restrictions Patient/family education Evaluate Response Weight back to baseline? Symptoms improved?

Common Complications Hypotension Do not hold beta-blocker or RAAS inhibiting medications if patient is asymptomatic Heart failure patients have a reduced cardiac output, therefore blood pressure is usually low Notify provider if BP is less than 90/50 mmhg or patient is symptomatic Hypotension & fluid retention --- reduce HF meds Hypotension & dehydrated --- reduce/hold diuretics Viral illness resulting in vomiting/diarrhea Hold diuretic to avoid dehydration 30-day Readmission Rates 30 day readmission rate--25% nationally Common Complications Illness resulting in worsening atrial fibrillation Need to control heart rates Change in patient's food intake Reduced appetite should result in weight loss Need to adjust goal dry weight parameters Important to assess for symptoms, not just monitor weight Treatment with steroids COPD flare, joint injections Frequently leads to fluid retention Follow Up Appointment within 7 calendar days of discharge HF clinic enrollment Aquaphoresis CardioMEM s OnTrack ipad monitoring Telemonitoring scales Devices (Latitude, Carelinks) Support Group Advanced HF consults

Advanced HF Consult Team approach lead by HF board certified Dr. Jamie Pelzel Discuss nature of illness Discuss prognosis At Stage D, determine appropriate pathway -Transplantation -LVAD -Palliative Care consult QUESTIONS??? HF Clinic: Heart and Vascular Clinic Open Monday through Friday- can accommodate same day appointments if needed Advanced practice providers working under the direction of Cardiology focused on HF specific Can assist with difficult to control CHF symptoms Can administer IV medications if needed No referral needed Please send weights, vital signs, and medication administration record to all appointments